Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Investor Presentation (April 2025)
24 slides from Prescient Therapeutics's investor presentation, Apr 17, 2025
Slide 1: Prescient Therapeutics – Investor Briefing
Prescient Therapeutics – Investor Briefing MELBOURNE Australia, 17th April 2025: Prescient Therapeutics Limited (ASX: PTX), a clinical stage oncology company developing personalised therapies for cancer, will be holding an investor briefing on Thursday, 17th April at 12pm (AEST). CEO James McDonnell
Slide 2: CellPryme-A and OmniCAR platforms
CellPryme-A: CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumour microenvironment. CellPryme-A significantly decreases suppressive regulatory T cells; increases expansion of CAR-T cells in vivo; increa
Slide 3: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather ar
Slide 4: For personal use only
For personal use only ASX: PTX
Slide 5: Disclaimer and Safe Harbor
DISCLAIMER AND SAFE HARBOR For personal use only Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts b
Slide 6: PTX-100 is one of the most advanced cancer therapies on the ASX
PTX-100 is one of the most advanced cancer therapies on the ASX For personal use only Overview Results & progress • One of the most advanced cancer therapies on ASX • Promising Phase 1b results for T-Cell Lymphoma • Treats high-mortality cancers with unmet need ✓ Strong response (64% halting or redu
Slide 7: PTX-100 First in Class Targeted Therapy
PTX-100 First in Class Targeted Therapy Inhibition of GGT-1 disrupts small GTPases including: For personal use only the RAS family pathway • Mutations in RAS are estimated to be responsible for approximately 22% of all human cancers1 • PTX-100 targets and blocks an enzyme called GGTase-1, disrupting
Slide 8: Cutaneous T-cell Lymphoma (CTCL) Overview
Cutaneous T-cell Lymphoma (CTCL) Overview For personal use only • A rare type of cancer of white blood cells (T cells), normally involved in immune function • These cancerous T cells travel to and live in the skin, where they grow and divide uncontrollably, attacking the skin • CTCLs include subtype
Slide 9: Cutaneous T-cell Lymphomas (CTCL): a serious unmet need
Cutaneous T-cell Lymphomas (CTCL) a serious unmet need For personal use only Professor Miles Prince “Unfortunately, T-Cell lymphomas (…) is universally incurable in patients that have not responded to initial therapy. So, we are in desperate need of a treatment that will allow patients to respond an
Slide 10: For personal use only
For personal use only 77
Slide 11: Before After patient responses
Before After For personal use only “We are seeing responses in our patients who weren’t responding to any other treatments” Professor H. Miles Prince Principal Investigator 8
Slide 12: PTX-100 Phase 1b responses: strong response rates
PTX-100 Phase 1b responses: Strong response rates in evaluable patients For personal use only PTX-100 Benchmark1 Lymphir2,3 (Phase 1B) Response Rate 30% 36% 45% Clinical Benefit 45% NA 64% Rate Duration of 9-13 months CTCL 6.5 months (CTCL) 10.7 months Response 3-4 Months PTCL Serious Adverse >30% 3
Slide 13: PTX-100: Favorable safety profile compared to peers
PTX-100: Favorable safety profile compared to peers Recommended CTCL drugs, as outlined in international cancer treatment guidelines, have For personal use only challenging safety profiles, with adverse events occurring in up to 70% of patients Adverse Events Associated with current Marketed Drugs*
Slide 14: Rationale of prioritising r/r CTCL for Ph2 trial
Rationale of prioritising r/r CTCL for Ph2 trial For personal use only CTCL PTCL • Higher confidence of PTX-100 in CTCL • Peripheral T Cell Lymphoma (PTCL) is more (more data; more responders) prevalent than CTCL, but even though PTCL is still an unmet need, it has more existing • Greater need for n
Slide 15: Progressing PTX-100 to Phase 2
Progressing PTX-100 to Phase 2 For personal use only Dose Confirmation r/r CTCL 500mg/m2 x 20 pts Randomization 2nd Line Enrolment Phase 2a Optimisation Phase 2b Efficacy DOC X40 X 75 pts patients (pts) 1000mg/m2 x 20 pts Up to 2 years Multicenter clinical trial • Phase 2a: N=40 pts with r/r CTCL (d
Slide 16: Aiming for shortened registrational pathway
Aiming for shortened registrational pathway For personal use only Regular drug development process Years & $$$ saved Potential for Registrational study Ada pte d from Capuano , A. et al; Front. In Pharmacol.; Feb 2019 13
Slide 17: Aiming for shortened registrational pathway
Aiming for shortened registrational pathway For personal use only Regular drug development process PTX-100 Benchmark1 (Phase 1B) Response Rate 30% 45% Clinical Benefit 45% 64% Rate Duration of 9-13 months CTCL Potential for 10.7 months Response 3-4 Months PTCL Registrational study Serious Adverse >3
Slide 18: Advantages of Orphan Drugs
Advantages of Orphan Drugs For personal use only Orphan 11.6% CAGR 7 7 years of guaranteed market exclusivity in US Non-orphan 7% CAGR (10 years in Europe) Higher prices Consistently higher sales growth than non-orphan drugs Sales are more resilient Total orphan sales to cycles to reach $US300B by 2
Slide 19: T-cell lymphomas (TCL): High unmet need = Large market opportunity
T-cell lymphomas (TCL): High unmet need = Large market opportunity For personal use only Total Addressable Market (TAM) CTCL US alone • 27,263 new cases / year in the 8 major • Incidence 3,000 patients /annum# markets • Almost all will relapse • Almost all will relapse • Combination therapy likely •
Slide 20: Key Milestones in the near future
Key Milestones in the near future: Implementation will drive value For personal use only Key Milestones Expected Timing (CY) First patient in and dosed with PTX-100 (FPID) April/May FDA Fast Track designation Q2 First US site activated and recruiting Q2/3 First European site activated and recruiting
Slide 21: First in Class PTX-100 beyond TCL
First in Class PTX-100 beyond TCL For personal use only • First in class enzyme inhibitor disrupting the RAS super - family pathway, in particular, RHO, RAC and RAL • 22% of all cancers have RAS involvement Examples: • The RAS super family of genes consists of RAL, RAC, RHO-A/B, plus N-RAS and K-RAS
Slide 22: Experienced team
Experienced team For personal use only • Experienced team of drug developers and deal makers with track record in blood cancers Management Team Experienced gained in global companies Board of Directors 19
Slide 23: Summing up PTX-100: Driving a major inflection point
Summing up PTX-100: Driving a major inflection point For personal use only Results: Timelines: Phase 1b • Phase 2a is starting now • 64% Clinical Benefit • Multiple sites globally • 10.7 months Duration of Response • International experts involved • 4% ≥ Grade 3 SAE • Recruitment will drive timing •
Slide 24: For personal use only
For personal use only ASX: PTX
Prescient Therapeutics — Investor Presentation (April 2025) on 6ix